MYC amplification in osteosarcoma linked to worse overall survival

In patients with osteosarcoma, MYC amplification may be a potential prognostic factor for poor outcomes, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

This study analyzed the genetic sequencing of 92 patients with osteosarcoma, of which 37% had metastatic disease at diagnosis. The 3-year overall survival (OS) was 71% for the entire study population, 56% for patients with metastatic disease at diagnosis, and 81% for patients with initially localized disease.

Genomic analysis found that 37% had alterations in TP53, 15% in RB1, 13% in CDKN2A, 12% in MYC, 12% in CDKN1A, 10% in ATRX, and 8% in CCND3.

Patients who had tumors with MYC amplification had a 3-year OS of 39% whereas patients without MYC amplification had a 3-year OS of 76%. The difference was borderline statistical significance (P = 0.051).

Reference

Marinoff A, et al. Characterizing the landscape of genomic variants in high-risk pediatric osteosarcoma. Presented at: 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program; May 29-31.